BPC-157 and Thymosin Beta-4 in Liver Injury and Fibrosis Models: Rat Studies, Stellate Cells and a Tβ4 Paradox

RESEARCH · BPC-157 + TB-500 · LIVER INJURY AND FIBROSIS

BPC-157 and Thymosin Beta-4 in Liver Injury and Fibrosis Models: Rat Studies, Stellate Cells and a Tβ4 Paradox

PurixLab’s BPC-157 + TB-500 10mg vial combines two research peptides: BPC-157, a 15-amino-acid fragment first studied in gastric models, and TB-500, a synthetic peptide commonly based on a short region of thymosin beta-4 (Tβ4). Our earlier articles cover the blend composition, gut mucosal models and the human data gap. This article looks at a different organ: the liver. Both peptides have been tested in rodent liver injury models, and the Tβ4 literature adds a twist, because the endogenous protein appears to work in opposite directions depending on how it is studied. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

BPC-157 in rat liver injury models

Almost all of the BPC-157 liver work comes from one research network in Zagreb, and it uses rats. The earliest study compared BPC-157 with bromocriptine, amantadine and somatostatin in three models: bile duct plus hepatic artery ligation, restraint stress and carbon tetrachloride (CCl4). BPC-157 prevented liver necrosis or fatty change in all three, the reference drugs had little or no protective action, and bilirubin and transaminase values tracked the tissue findings [1]. Later papers from the same group extended this to:

  • Chronic alcohol. Rats drinking alcohol for 3 months developed portal hypertension, enlarged hepatocytes and steatosis; BPC-157 and propranolol, but not ranitidine, prevented or reversed the rise in portal pressure [2].
  • Bile duct ligation. In rats followed for up to 8 weeks, BPC-157 was reported to counteract jaundice, ascites, necrosis, stellate cell α-SMA staining, collagen deposition and raised liver enzymes, and portal hypertension either did not develop or abated quickly [3].
  • Drug toxicity. After an extreme paracetamol overdose (5 g/kg), rats developed hepatic encephalopathy with generalised convulsions; BPC-157 given early or 3 hours later reduced liver and brain lesions, enzyme and ammonium values [4]. A similar pattern was reported for chronic ibuprofen given for 4 weeks [5].
  • Vascular occlusion. In a Pringle manoeuvre model (portal triad clamped for 30 min) and a Budd-Chiari model (suprahepatic caval occlusion), the authors described rapid recruitment of collateral venous pathways together with reduced portal and caval hypertension and thrombosis [6,7].

One study from outside that network exists. In mice given a single 12 Gy of radiation to induce acute liver injury, oral BPC-157 lowered AST and ALT, reduced apoptosis and lipid accumulation, and increased Kruppel-like factor 4 (KLF4). Knocking down KLF4 in rat liver cells abolished the protective effect in vitro [8].

Two caveats run through this literature. First, independent replication is thin: apart from the radiation study, the liver findings come from one group. Second, several abstracts use strong language, describing BPC-157 as having “cured” bile duct ligated rats [3] or as a “highly effective paracetamol antidote” [4]. These are rat studies with endpoints chosen by the investigators, not clinical evidence.

Exogenous Tβ4 in mouse and rat liver models

A separate set of studies, mostly from groups in the United States and China, gave full-length Tβ4 to rodents:

  • CCl4. In both mice and rats, Tβ4 attenuated CCl4-induced rises in ALT, AST and malondialdehyde, loss of antioxidants, inflammatory and fibrotic markers, necrosis and collagen deposition, along with reduced NF-κB p65 [9]. An earlier preliminary rat report described prevention of necrosis and of stellate cell activation markers, with PPARγ restored and MeCP2 reduced [10].
  • Paracetamol. In mice, Tβ4 given at 0, 2 and 4 h after paracetamol reduced ALT, AST, necrosis, HMGB1 release and oxidative stress; blocking autophagy with chloroquine removed the protection [11].
  • Alcohol plus LPS. In mice fed 5% ethanol for 4 weeks with an ethanol binge and LPS, Tβ4 prevented rises in injury markers, oxidative stress, NF-κB activation and fibrogenic genes [12].
  • Cholestasis. After bile duct ligation in mice, Tβ4 reduced mortality, portal fibrosis and collagen content, with lower TGFβ1 and PDGFRβ [13].
  • Fatty liver. In rats on a high-fat diet, Tβ4 improved lipid and inflammatory indexes, and silencing GPX4 weakened its effect, which the authors linked to ferroptosis [14].

Stellate cells and the actin-binding motif

Hepatic stellate cells (HSCs) are the main producers of type I collagen in the fibrotic liver [15]. In cultured human HSCs, Tβ4 upregulated hepatocyte growth factor and downregulated the PDGF-β receptor, without changing collagen mRNA [15]. A later study found Tβ4 inhibited PDGF-BB-driven proliferation and migration and blocked AKT phosphorylation; the authors proposed that Tβ4, by sequestering actin, prevents AKT from binding to it [16].

The same group then compared two Tβ4 fragments. The actin-binding fragment LKKTETQ (17-23aa) inhibited PDGF-BB-induced upregulation of the PDGFβ receptor, α-SMA and collagen 1 and blunted AKT phosphorylation, while the amino-terminal fragment (1-15aa) had no effect on HSC proliferation or migration [17]. That matters for TB-500 research, because LKKTETQ is the motif on which TB-500 is commonly based. It is still one cell culture study, and it did not test the combined BPC-157 + TB-500 material.

The paradox: endogenous Tβ4 in damaged liver

Studies of the body’s own Tβ4 point in different directions:

  • Tβ4 is strongly expressed in normal adult human hepatocytes, most prominently in zone 3 around the terminal vein, across thirty-five normal liver samples [18].
  • One group found Tβ4 expression was reduced as human liver fibrosis progressed, and that depleting Tβ4 in LX-2 stellate cells increased their proliferation, migration and activation through PI3K/Akt [19].
  • Another group found the opposite. Tβ4 rose in activated HSCs and in human livers with advanced fibrosis, and silencing it in LX-2 cells lowered activation genes [20]. Tβ4-overexpressing mice given CCl4 were more susceptible to fibrosis, with higher Hedgehog activity [21], and deleting Tβ4 only in activated HSCs reduced fibrosis in both CCl4 and bile duct ligation models [22].

These results are not necessarily contradictory. Adding the peptide from outside a cell, deleting it inside one cell type, and measuring tissue levels are different experiments. But they show that “Tβ4 is antifibrotic” is too simple, and that the direction of an effect may depend on the cell, the compartment and the model.

What remains open

  • No study we found tested BPC-157 and TB-500 together in a liver model, or compared TB-500 directly with full-length Tβ4 in vivo.
  • The BPC-157 liver findings need replication outside the originating network.
  • Endpoints are mostly enzymes, histology scores and markers at short time points; few studies assess long-term fibrosis regression.
  • There are no human liver studies for either peptide.

BPC-157 + TB-500 10mg at PurixLab

BPC-157 + TB-500 10mg: a labelled lyophilized research vial with BPC-157 5mg + TB-500 5mg per vial (10mg total), C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View BPC-157 + TB-500 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Sikiric P, Seiwerth S, Grabarevic Z, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci. 1993;53(18):PL291-6. PubMed 7901724 · doi:10.1016/0024-3205(93)90589-u
  2. Prkacin I, Separovic J, Aralicia G, et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris. 2001;95(1-6):315-24. PubMed 11595456 · doi:10.1016/s0928-4257(01)00044-4
  3. Sever AZ, Sever M, Vidovic T, et al. Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation. Eur J Pharmacol. 2019;847:130-142. PubMed 30690000 · doi:10.1016/j.ejphar.2019.01.030
  4. Ilic S, Drmic D, Zarkovic K, et al. High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats. A counteraction with the stable gastric pentadecapeptide BPC 157 (PL 14736). J Physiol Pharmacol. 2010;61(2):241-50. PubMed 20436226
  5. Ilic S, Drmic D, Zarkovic K, et al. Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. Eur J Pharmacol. 2011;667(1-3):322-9. PubMed 21645505 · doi:10.1016/j.ejphar.2011.05.038
  6. Kolovrat M, Gojkovic S, Krezic I, et al. Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. World J Hepatol. 2020;12(5):184-206. PubMed 32547687 · PMC7280862 · doi:10.4254/wjh.v12.i5.184
  7. Gojkovic S, Krezic I, Vrdoljak B, et al. Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats. World J Gastrointest Pathophysiol. 2020;11(1):1-19. PubMed 32226643 · PMC7093306 · doi:10.4291/wjgp.v11.i1.1
  8. Huang BS, Huang SC, Chen FH, et al. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro. Life Sci. 2022;310:121072. PubMed 36228773 · doi:10.1016/j.lfs.2022.121072
  9. Li X, Wang L, Chen C. Effects of exogenous thymosin β4 on carbon tetrachloride-induced liver injury and fibrosis. Sci Rep. 2017;7(1):5872. PubMed 28724974 · PMC5517632 · doi:10.1038/s41598-017-06318-5
  10. Reyes-Gordillo K, Shah R, Arellanes-Robledo J, et al. Protective effects of thymosin β4 on carbon tetrachloride-induced acute hepatotoxicity in rats. Ann N Y Acad Sci. 2012;1269:61-8. PubMed 23045971 · doi:10.1111/j.1749-6632.2012.06728.x
  11. Wang L, Li X, Chen C. Inhibition of acetaminophen-induced hepatotoxicity in mice by exogenous thymosinβ4 treatment. Int Immunopharmacol. 2018;61:20-28. PubMed 29793165 · doi:10.1016/j.intimp.2018.05.011
  12. Shah R, Reyes-Gordillo K, Cheng Y, et al. Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice. Oxid Med Cell Longev. 2018;2018:9630175. PubMed 30116499 · PMC6079392 · doi:10.1155/2018/9630175
  13. Chen C, Li X, Wang L. Thymosinβ4 alleviates cholestatic liver fibrosis in mice through downregulating PDGF/PDGFR and TGFβ/Smad pathways. Dig Liver Dis. 2020;52(3):324-330. PubMed 31542221 · doi:10.1016/j.dld.2019.08.014
  14. Zhu Z, Zhang Y, Huang X, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4. Eur J Pharmacol. 2021;908:174351. PubMed 34280397 · doi:10.1016/j.ejphar.2021.174351
  15. Barnaeva E, Nadezhda A, Hannappel E, et al. Thymosin beta4 upregulates the expression of hepatocyte growth factor and downregulates the expression of PDGF-beta receptor in human hepatic stellate cells. Ann N Y Acad Sci. 2007;1112:154-60. PubMed 17584975 · doi:10.1196/annals.1415.035
  16. Reyes-Gordillo K, Shah R, Popratiloff A, et al. Thymosin-β4 (Tβ4) blunts PDGF-dependent phosphorylation and binding of AKT to actin in hepatic stellate cells. Am J Pathol. 2011;178(5):2100-8. PubMed 21514425 · PMC3081167 · doi:10.1016/j.ajpath.2011.01.025
  17. Shah R, Reyes-Gordillo K, Rojkind M. Thymosin β4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opin Biol Ther. 2018;18(sup1):177-184. PubMed 30063851 · PMC6748868 · doi:10.1080/14712598.2018.1478961
  18. Nemolato S, Van Eyken P, Cabras T, et al. Expression pattern of thymosin beta 4 in the adult human liver. Eur J Histochem. 2011;55(3):e25. PubMed 22073372 · PMC3203477 · doi:10.4081/ejh.2011.e25
  19. Xiao Y, Qu C, Ge W, et al. Depletion of thymosin β4 promotes the proliferation, migration, and activation of human hepatic stellate cells. Cell Physiol Biochem. 2014;34(2):356-67. PubMed 25060912 · doi:10.1159/000363005
  20. Kim J, Wang S, Hyun J, et al. Hepatic stellate cells express thymosin Beta 4 in chronically damaged liver. PLoS One. 2015;10(3):e0122758. PubMed 25826335 · PMC4380456 · doi:10.1371/journal.pone.0122758
  21. Kim J, Hyun J, Wang S, et al. Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling. Sci Rep. 2017;7(1):3815. PubMed 28630423 · PMC5476572 · doi:10.1038/s41598-017-03782-x
  22. Kim J, Lee C, Han J, et al. Targeted Deletion of Thymosin Beta 4 in Hepatic Stellate Cells Ameliorates Liver Fibrosis in a Transgenic Mouse Model. Cells. 2023;12(12):1658. PubMed 37371128 · PMC10297343 · doi:10.3390/cells12121658

Leave a Comment

Your email address will not be published. Required fields are marked *